This study is a 56-week, open-label, one-arm extension study in participants who have completed the CRTH258A2303 study (TALON). Participants who consent and meet all the inclusion and none of the exclusion criteria will be enrolled into this extension study and receive brolucizumab 6 mg in a TtC regimen, irrespective of the treatment received in the core study.~It is estimated that 622 participants from the core study will enter the extension study (10% dropout rate expected). The maximum study duration for one participant is 56 weeks, including post-treatment follow-up.~There will be two periods in this study:~Treat-to-Control treatment period: from Baseline (Day 1) to Week 52~Post-treatment follow-up period: from Week 52 to Week 56.~All participants will be treated with brolucizumab regardless of their treatment in the TALON study (brolucizumab or aflibercept).~Treatment intervals can then be extended by 4 weeks at a time based on the investigator's judgment of visual and/or anatomic outcomes. The treatment intervals should be by 4 weeks at a time if disease activity recurs.
The purpose of this extension study is to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The main objective is to assess brolucizumab's potential for long durability up to 20 weeks.~All eligible participants will be treated with brolucizumab regardless of their treatment in the TALON study.~The study period is 56 weeks including post-treatment follow-up.